A Phase 2 interventional study of Losartan and Placebo in Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI and Mucopolysaccharidoses, sponsored by Hospital de Clinicas de Porto Alegre. Status unknown at 1 site in Brazil. Open to participants aged 10 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-12-19.
Sponsored by Hospital de Clinicas de Porto Alegre · Phase 2, Interventional, and Treatment
Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. For some of the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is no effective treatment currently available. Losartan, on the other hand, has been shown to be an effective drug for dilation of the aortic root, at least in animal models. This study aims to evaluate the safety and efficacy of losartan in patients with MPS VI and other mucopolysaccharidoses.
Mucopolysaccharidoses (MPS) are a group of lysosomal diseases characterized by deficiency of enzymes responsible for the degradation of glycosaminoglycans. MPS are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. Enzyme replacement therapy and bone marrow transplantation, despite being well established treatments, are not yet capable of reversing or preventing the progression of some of the cardiological manifestations of MPS. On the other hand, these patients may benefit from other conventional drug or surgical treatment, which can be instituted at an appropriate time if there is a better understanding of how these manifestations progress. In particular, the occurrence of aortic root dilation, although described in animal models, has only recently been evaluated in the studies on mucopolysaccharidoses.
In addition, verifying the effectiveness of losartan in controlling these manifestations in the animal model opens the perspective of clinical use of this drug. Losartan is a low-cost drug and, if its efficacy is demonstrated, may represent an accessible therapy directed at the unmet needs of these patients.
41 studies on the registry are indexed under Osteochondrodysplasias; 11 are open to participants now.
This study's enrollment of 10 is below the median of 77 across 19 interventional studies indexed under Osteochondrodysplasias.
Browse Osteochondrodysplasias studies →Hospital de Clinicas de Porto Alegre is the lead sponsor of 450 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
Drug: Losartan
Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
Drug: Placebo
Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
Adverse events related to losartan use
The frequency of adverse events after 12 months will be compared among the groups
Time frame: 12 months
Z score of maximal aortic root diameter measured by Valsalva sinus
Reduction over time in the Z score of maximal aortic root diameter measured by Valsalva sinus echocardiogram between the baseline assessment and 12 months after treatment with losartan.
Time frame: 12 months
Changes of serum levels of transforming growth factor (TGF-Beta-1)
Changes of serum levels of transforming growth factor (TGF-Beta-1) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of brain-type natriuretic peptide (BNP)
Changes of serum levels of brain-type natriuretic peptide between baseline and 12 months
Time frame: 12 months
Changes of serum levels of N-terminal pro b-type natriuretic peptide (NT-ProBNP)
Changes of serum levels of N-terminal pro b-type natriuretic (NT-ProBNP) peptide between baseline and 12 months
Time frame: 12 months
Changes of serum levels of creatine kinase-myocardial ban (ck-mb)
Changes of serum levels of creatine kinase-myocardial ban (ck-mb) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6)
Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16)
Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Endocan-1 (ESM-1)
Changes of serum levels of Endocan-1 (ESM-1) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Placental growth factor (PLGF)
Changes of serum levels ofPlacental growth factor (PLGF) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Fatty acid binding protein 3 (FAPB3)
Changes of serum levels of Fatty acid binding protein 3 (FAPB3) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Fatty acid binding protein 4 (FAPB4)
Changes of serum levels of Fatty acid binding protein 4 (FAPB4) between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Oncostatin M
Changes of serum levels of Oncostatin M between baseline and 12 months
Time frame: 12 months
Changes of serum levels of Troponin I
Changes of serum levels of Troponin I between baseline and 12 months
Time frame: 12 months
Changes of ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months.
Reduction over time in the ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months.
Time frame: 12 months
Changes in mitral valve regurgitation
Alteration of the parameter of mitral valve regurgitation as assessed by a semi-quantitative echocardiographic method between the baseline and 12 months.
Time frame: 12 months
Changes in aortic valve regurgitation
Alteration of the parameter of aortic valve regurgitation as assessed by a semi-quantitative echocardiographic method between the baseline and 12 months.
Time frame: 12 months
Changes in ejection fraction
Alteration of the ejection fraction measurement as assessed by echocardiography between the baseline and 12 months.
Time frame: 12 months
Changes in left ventricular longitudinal strain
Alteration of the measurement of left ventricular longitudinal strain as assessed by echocardiography between the baseline and 12 months.
Time frame: 12 months
Changes in E/A ratio
Alteration of the parameter E/A ratio as assessed by echocardiography between the baseline and 12 months .
Time frame: 12 months
Changes in E/e' ratio
Alteration of the parameter E/e' ratio as assessed by echocardiography between the baseline and 12 months.
Time frame: 12 months
Glycosaminoglycan after 6 months
Difference in urinary glycosaminoglycan levels after 6 months
Time frame: 6 months
Glycosaminoglycan after 12 months
Difference in urinary glycosaminoglycan levels after 12 months
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Clinicas de Porto Alegre